Sutro Biopharma Inc [STRO] stock prices are up 5.74% to $13.82 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The STRO shares have gain 13.00% over the last week, with a monthly amount glided 40.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sutro Biopharma Inc [NASDAQ: STRO] stock has seen the most recent analyst activity on June 16, 2025, when Piper Sandler upgraded its rating to a Overweight but kept the price target unchanged to $2 for it. Previously, H.C. Wainwright downgraded its rating to Neutral on March 17, 2025. On March 14, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $2 on the stock. Citizens JMP downgraded its rating to a Mkt Perform. BofA Securities downgraded its rating to a Underperform and reduced its price target to $1 on March 14, 2025. BofA Securities started tracking with a Buy rating for this stock on May 08, 2024, and assigned it a price target of $12. In a note dated November 09, 2023, Deutsche Bank initiated an Buy rating and provided a target price of $12 on this stock.
The stock price of Sutro Biopharma Inc [STRO] has been fluctuating between $5.23 and $21.50 over the past year. Currently, Wall Street analysts expect the stock to reach $9.86 within the next 12 months. Sutro Biopharma Inc [NASDAQ: STRO] shares were valued at $13.82 at the most recent close of the market. An investor can expect a potential drop of -28.65% based on the average STRO price forecast.
Analyzing the STRO fundamentals
The Sutro Biopharma Inc [NASDAQ:STRO] reported sales of 105.65M for trailing twelve months, representing a surge of 13.77%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -1.76%, Pretax Profit Margin comes in at -2.03%, and Net Profit Margin reading is -2.05%. To continue investigating profitability, this company’s Return on Assets is posted at -1.03, Equity is 8.62 and Total Capital is -1.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Sutro Biopharma Inc [NASDAQ:STRO]’s Current Ratio is 2.53. Further, the Quick Ratio stands at 2.53, while the Cash Ratio is 0.92. Considering the valuation of this stock, the price to sales ratio is 1.11.
Transactions by insiders
Recent insider trading involved Gerber Hans-Peter, CHIEF SCIENTIFIC OFFICER, that happened on Oct 15 ’25 when 17000.0 shares were purchased. CFO, Chow Gregory K. completed a deal on Oct 15 ’25 to buy 19750.0 shares. Meanwhile, Chief Executive Officer Chung Jane bought 12500.0 shares on Oct 15 ’25.
